Compare CREX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | VERU |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 40.9M |
| IPO Year | 2015 | 1996 |
| Metric | CREX | VERU |
|---|---|---|
| Price | $3.78 | $2.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 26.6K | ★ 53.4K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,437,000.00 | $16,296,958.00 |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.19 | $0.36 |
| 52 Week High | $4.42 | $4.59 |
| Indicator | CREX | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 56.93 |
| Support Level | $3.52 | $2.12 |
| Resistance Level | $3.99 | $2.67 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 75.57 | 96.67 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.